The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.
World of Genomics: South Korea frontlinegenomics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from frontlinegenomics.com Daily Mail and Mail on Sunday newspapers.